Disclosed is a Pharmaceutical composition containing as an active ingredient an effective amount of inhibitors of SAA, CRP and/or CXCL-1 activity, or a pharmaceutically acceptable salt for the use in the treatment of dysregulated inflammatory diseases or conditions and/or malignancies and/or cancer and/or tumors by influencing the activity of myeloid-derived suppressor cells (MDSC), as well as the use of an effective amount of inhibitors of SAA, CRP and/or CXCL-1 activity or a pharmaceutically acceptable salt thereof for reducing the frequency, accumulation and/or activity, and/or for depleting MDSC for treating diseases or conditions and a Method for the treatment of malignancies and/or cancer and/or tumors in individuals by administering an effective amount of an inhibitor of SAA, CRP and/or CXCL-1 or a pharmaceutically acceptable salt thereof.
